Innovent Biologics said the first patient has been dosed in a pivotal registrational study in China for IBI363/TAK-928, its PD-1/IL-2α-biased bispecific fusion protein. The trial is testing the drug in combination with bevacizumab for patients with late-line advanced colorectal cancer.
The start of dosing marks an important development for the program because a registrational study is typically intended to support future regulatory review if the results are positive. Innovent announced the milestone from San Francisco and Suzhou, underscoring the company’s cross-border presence as it advances oncology treatments.
According to the announcement, the study focuses on advanced colorectal cancer patients who are receiving treatment in later lines, an area where new options remain in demand. The combination of IBI363/TAK-928 with bevacizumab highlights Innovent’s effort to evaluate a novel immunotherapy-based approach in this hard-to-treat setting.
Innovent, listed in Hong Kong, develops, manufactures and commercializes medicines across oncology and other disease areas. With first-patient dosing now underway, the colorectal cancer study becomes a key part of the company’s late-stage clinical pipeline in China.
